LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

Search

Ascendis Pharma A-S ADR

Open

SectorHealthcare

172.01 0.29

Overview

Share price change

24h

Current

Min

168.26

Max

173.47

Key metrics

By Trading Economics

Income

-56M

-95M

Sales

-73M

101M

EPS

-1.58

Profit margin

-93.732

Employees

1,017

EBITDA

-11M

-49M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+29.4% upside

Dividends

By Dow Jones

Next Earnings

2 wrz 2025

Market Stats

By TradingEconomics

Market Cap

720M

11B

Previous open

171.72

Previous close

172.01

News Sentiment

By Acuity

50%

50%

138 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 sie 2024, 13:03 UTC

Major Market Movers

Ascendis Pharma Shares Climb on U.S. FDA Approval for Hypoparathyroidism Treatment Yorvipath

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

29.4% upside

12 Months Forecast

Average 222.85 USD  29.4%

High 289 USD

Low 194 USD

Based on 14 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

14

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

138 / 380 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.